Peptide Decoding
All stacks Stacks / Growth hormone

CJC-1295 + Ipamorelin + IGF-1 LR3

Corrected November 13, 2026: CJC-1295 trial figure, IGF-1 LR3 clearance

The third compound removes the one safety feature the first two were chosen for.

Corrected November 9, 2026: 503A compounding status of CJC-1295 and ipamorelin

The standard growth hormone pair is picked over injected HGH because the body stays in control of how much it releases. IGF-1 LR3 is added to push harder, and it bypasses that control entirely. It is also the second time the stack pays for the same hormone.

Reported forLean massRecoverySleepFat loss
the advanced gh stack  ·  cjc/ipa/igf  ·  the anabolic stack
Raises the signal
A GHRH analog telling the pituitary to release more growth hormone. Raised IGF-1 one and a half to three fold after a single dose in its human trial.
Research only
Fires the pulse
Acts on the ghrelin receptor to trigger release without raising hunger or stress hormones. Failed two Phase 2 trials.
Research only
Skips the chain
The hormone growth hormone produces, modified to resist the proteins that normally clear it. Supplied directly rather than made by the body.
No human trials
Why people stack these

The advanced version of the most common stack.

CJC-1295 with ipamorelin is the most searched pairing in the category. This is what people add when it has not done what they hoped.

The reasoning is that the pair works upstream, prompting the body to make more growth hormone, which the liver then converts into IGF-1. IGF-1 is the hormone that does the building. So supplying it directly is presented as cutting out the middleman.

Vendor guides describe this as being for experienced users who have completed at least one cycle of the pair and are willing to commit to bloodwork. That framing is doing a lot of work, and the warnings attached to it are more informative than the pitch.

Benefits people are after

Four benefits, and how well each one holds up.

Higher IGF-1The measurable effect, and the reason for all three compounds.
CJC-1295 raised it 1.5 to 3 fold
More muscle than the pair aloneThe reason the third compound is added.
No human trial of IGF-1 LR3 at all
Faster recoveryWhat most people are chasing.
Never measured for any of the three
Keeping the body's own controlThe stated advantage of secretagogues over injected HGH.
The third compound removes it

The top row is proven and it is a blood marker. The bottom row is the one this page is about.

Does it work?

Three questions, answered before anything else.

Does IGF-1 LR3 have human evidence?
None. No controlled human study exists. The case for it rests on mechanism, animal work and community use.
Does it break the feedback loop?
Yes, and that is the point of it. It bypasses control. Secretagogues are chosen because somatostatin can still shut the system down. Supplying IGF-1 directly removes that brake.
Is the stack buying IGF-1 twice?
In effect, yes. The pair already raises it. CJC-1295 raised IGF-1 one and a half to three fold after a single dose in its human trial. The third compound adds more of the same hormone by a different route.
The feature being removed

Secretagogues are chosen for the brake. This takes the brake off.

The argument for CJC-1295 and ipamorelin over injected growth hormone has always been the same one. They ask the pituitary to release more rather than supplying hormone from outside, so the body's own regulation stays intact; in healthy men, CJC-1295 raised growth hormone output while the normal pulsing pattern was preserved.[1]

Somatostatin is the brake. When growth hormone climbs, somatostatin rises and shuts the release down. That is why a secretagogue cannot push the system past a ceiling, and it is presented as the safety advantage of the whole class.

Step 1
CJC-1295 signals the pituitary through the GHRH receptor.
Step 2
Ipamorelin triggers the pulse through the ghrelin receptor.
Step 3
Growth hormone reaches the liver, which converts it to IGF-1.
Step 4
Rising output raises somatostatin, which shuts the release down.
Bypassed
IGF-1 LR3 is injected at the end of the chain. Steps 1 to 4 no longer govern how much IGF-1 is circulating, because it is no longer being made.

The contrast is simple. The pair is self-limiting because the pituitary still decides how much to release. IGF-1 LR3 acts on the receptor directly, outside that control.

So the third compound removes the property the first two were selected for. Someone willing to give that up has fewer reasons left to prefer secretagogues over growth hormone itself, which is a question the guides selling this stack do not ask.

The same hormone, twice

The pair already raises IGF-1.

CJC-1295's human trial is the strongest evidence anywhere in this stack. A single dose produced growth hormone elevation of two to ten fold lasting six days or more, with IGF-1 rising one and a half to three fold. After two or three doses given weekly or every other week, mean IGF-1 stayed above baseline for up to 28 days, and no serious adverse reactions were reported. That trial used CJC-1295 with DAC, the long-acting form. The no-DAC version sold for this stack is a different molecule and was not what the trial tested.[2]

That is the same endpoint the third compound is bought for. The stack is not covering three mechanisms; it is raising one hormone by two routes and then supplying the hormone itself.

The same pattern appears on the tirzepatide and retatrutide page, where two drugs share two of three receptors, and on the NAD+ trio, where all three compounds converge on one molecule.

That trial used CJC-1295 with DAC, the long-acting version. Most blends sold today use the version without it. The pair's own page covers that gap.

What IGF-1 LR3 is

Modified so the body cannot clear it.

Natural IGF-1 is controlled after release as well as before it. Binding proteins hold most of it inactive, releasing it gradually, which keeps free levels in a narrow range.

IGF-1 LR3 is engineered to escape those proteins. That is the modification, and it is why the compound is potent. In rats the analog is cleared from the blood faster than IGF-1, not slower, yet stays more potent, because the binding proteins no longer hold it back from tissue.[3]

The feature and the risk are the same property. There is no version of this compound that is strong without also being hard to switch off.

Two practical consequences follow. IGF-1 has insulin-like activity, so low blood sugar is a recognized concern: the approved IGF-1 drug carries a warning for severe hypoglycemia, and binding-protein-resistant analogs were two to three times more potent than IGF-1 at lowering glucose in pigs and marmosets.[4][5] Vendor guides recommend limiting use to a few weeks on the grounds that the receptor downregulates with continuous exposure.

No controlled human study has tested any of this. The published record for IGF-1 LR3 in healthy adults is empty.

The question worth asking a doctor

IGF-1 and cancer risk.

IGF-1 drives cell growth and division. That is what makes it useful for building tissue, and it is why elevated levels have been studied in cancer research for decades.

A 2020 analysis of the UK Biobank cohort found a small rise in total cancer risk with higher circulating IGF-1, about 3 percent per 5 nmol/L, with positive associations for breast, prostate and colorectal cancer among others and inverse associations for a few sites, including lung and liver.[6] That is observational work, meaning it shows an association rather than proving that raising IGF-1 causes cancer.

The approved IGF-1 drug, mecasermin, is contraindicated in anyone with active cancer or a history of it, and guides for this stack carry the same exclusion.[5] Uncontrolled diabetes and significant insulin resistance appear alongside it, since growth hormone opposes insulin.

Vendor guides for this stack describe bloodwork as mandatory rather than advisable, on the grounds that supraphysiological IGF-1 and insulin resistance can develop without symptoms. Anyone running three compounds aimed at one hormone has a clear reason to measure it.

What it costs

The third compound costs more than the first two together.

IGF-1 LR3 is the expensive part. At the cheapest in-stock listings it costs more than CJC-1295 and ipamorelin combined.[7]

Buying the first two premixed raises the total, since the CJC blend is cheaper per milligram than separate vials but sold in a larger vial. Nobody sells all three together.

Two blends pair IGF-1 LR3 with BPC-157, one of them adding TB-500. Both cost several times any single vial here, and neither states how much of each compound it contains.[7]

CJC-1295 no DAC, lowest in-stock single listing
$13.74
Ipamorelin, lowest in-stock single listing
$9.34
IGF-1 LR3, lowest of 129 single-compound listings
$8.99
All three, bought separately
$32.07
Status and sport

Nothing approved, and all three banned.

None of the three has FDA approval. CJC-1295's 503A nomination was withdrawn after previously being in Category 2. Ipamorelin's 503A nomination was also withdrawn; ipamorelin acetate remains in 503B Category 2, where it was placed on September 29, 2023. Neither is in a 503A category. Neither can be compounded under 503A.[8][9][10]

WADA bans all three at all times, in and out of competition. Growth hormone releasing factors and IGF-1 analogs are both listed, so a tested athlete taking this stack has committed a doping violation on three counts.

IGF-1 LR3 is sold as a research chemical with no approved label anywhere. Vials sold as research chemicals are made outside any approved manufacturing control, so purity and sterility depend entirely on the supplier.

Vendor guides also warn against use under 25, since growth plates may still be open in some people.

Common questions

What people ask about this stack

Is adding IGF-1 LR3 worth it?

No human trial has tested it, so the honest answer is that nobody knows. IGF-1 LR3 has no controlled human study for body recomposition, and the combination of all three has never been tested either. What is documented is that the third compound removes the feedback control that makes secretagogues appealing. CJC-1295 on its own already raised IGF-1 one and a half to three fold in its human trial.

Why does bypassing feedback matter?

Feedback is the reason people choose secretagogues over injected growth hormone. When output rises, somatostatin rises with it and shuts release down, so the system cannot be pushed past a ceiling. IGF-1 LR3 is injected at the end of that chain, so circulating levels no longer depend on it. The pair is self-limiting. IGF-1 LR3 is not.

What makes IGF-1 LR3 different from IGF-1?

IGF-1 LR3 is modified to escape the binding proteins that normally hold most IGF-1 inactive and release it gradually. That modification is why the compound is potent: in animals it is cleared from the blood faster than IGF-1 yet acts more strongly on tissue. The strength and the risk come from the same property, so there is no version that is strong without also being hard to switch off.

What are the risks?

Low blood sugar is recognized, since IGF-1 has insulin-like activity. Receptor downregulation is why guides limit use to a few weeks. The larger question is cancer risk: a 2020 UK Biobank analysis found a small rise in total cancer risk with higher circulating IGF-1 and positive associations for several sites, which is observational rather than causal. The approved IGF-1 drug is contraindicated in anyone with active or previous cancer, and guides for this stack list uncontrolled diabetes alongside it.

What does it cost?

IGF-1 LR3 is the expensive part, costing more on its own than CJC-1295 and ipamorelin combined. Nobody sells all three premixed. Two blends pair IGF-1 LR3 with BPC-157, one of them adding TB-500, and neither states how much of each compound it contains. Current prices for all three are on the page above.

Can athletes take this stack?

No. All three are banned by WADA at all times, in and out of competition. Growth hormone releasing factors cover CJC-1295, ghrelin receptor agonists cover ipamorelin, and IGF-1 analogs cover IGF-1 LR3, so a tested athlete has committed a violation on three separate counts. Compare against the other stacks.

References

What this page is built on

  • 01Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 2006;91(12):4792-4797. PMID 17018654, DOI 10.1210/jc.2006-1702. Healthy men aged 20 to 40, overnight sampling every 20 minutes before and one week after a single 60 or 90 µg/kg injection of CJC-1295 with DAC. GH secretion rose with pulsatility preserved; trough GH rose 7.5 fold, mean GH 46 percent and IGF-1 45 percent.
    PEER REVIEWED CLINICAL STUDY, ABSTRACT READ.
  • 02Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006;91(3):799-805. PMID 16352683, DOI 10.1210/jc.2005-1536. Two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, using CJC-1295 with DAC. After a single injection, mean GH rose 2 to 10 fold for 6 days or more and mean IGF-1 rose 1.5 to 3 fold for 9 to 11 days; estimated half-life 5.8 to 8.1 days. After multiple doses, mean IGF-1 stayed above baseline for up to 28 days. No serious adverse reactions were reported.
    PEER REVIEWED RANDOMIZED TRIALS, ABSTRACT READ.
  • 03Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. Journal of Endocrinology, 1996;150(1):77-84. PMID 8708565, DOI 10.1677/joe.0.1500077. Rat study. LR3 IGF-I has very low affinity for the IGF binding proteins and is cleared from the circulation more quickly than IGF-I, yet injected LR3 IGF-I kept superior potency to injected IGF-I for several actions.
    PEER REVIEWED ANIMAL STUDY, ABSTRACT READ.
  • 04Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. Journal of Endocrinology, 1997;155(2):377-386. DOI 10.1677/joe.0.1550377. Binding-protein-resistant variants including LR3 IGF-I were two to three times more potent than IGF-I at lowering plasma glucose, with a cumulative hypoglycemic effect about twice that of IGF-I at glucose-equipotent doses.
    PEER REVIEWED ANIMAL STUDY, ABSTRACT READ.
  • 05U.S. Food and Drug Administration. INCRELEX (mecasermin) injection, prescribing information, revised July 2025. FDA label (PDF). The approved recombinant IGF-1 drug. Contraindicated in malignant neoplasia or a history of malignancy and in closed epiphyses; warnings for severe hypoglycemia, including hypoglycemic seizures, because of its insulin-like effects.
    REGULATORY DOCUMENT, FDA-APPROVED LABEL, READ.
  • 06Qian F, Huo D. Circulating insulin-like growth factor-1 and risk of total and 19 site-specific cancers: cohort study analyses from the UK Biobank. Cancer Epidemiology, Biomarkers and Prevention, 2020. PMC7642199. Prospective analysis of 412,645 UK Biobank participants, median follow-up 7.2 years. Total cancer risk rose about 3 percent per 5 nmol/L of IGF-1 in both sexes, with positive associations for breast, prostate, colorectal, melanoma, kidney and thyroid cancer and inverse associations for lung, ovarian, head and neck and liver cancer.
    PEER REVIEWED PROSPECTIVE COHORT, OPEN ACCESS, ABSTRACT READ.
  • 07Peptide Decoding vendor pricing data, November 21, 2026. Lowest in-stock single-compound listings for CJC-1295 no DAC, ipamorelin and IGF-1 LR3, computed at page load. No premixed listing of all three. Two blends containing IGF-1 LR3 with BPC-157, one adding TB-500, neither stating composition.
    OWN DATA, OUR OWN DATASET, COMPUTED AT PAGE LOAD, NO EXTERNAL LINK.
  • 08FDA 503A list, updated May 14, 2026
  • 09FDA 503B list, updated March 21, 2025
  • 10FDA safety-risks page: bulk drug substances nominated but withdrawn
Last reviewed November 13, 2026 · No doses appear on this page by design · Nothing here is a recommendation